Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1570)	2/16/2006 3:20:39 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

TRMS Seems to have found support at the $11 level. The stock is up around 5% for the day and traded at 12.58 at 11.50AM bigcharts.marketwatch.com It is now over one year since the FDA approved Fuzeon for HIV treatment and TRMS & Roche announced last week some details on two next-generation HIV fusion inhibitor peptide candidates . Some advantages of TRI-1144 and TRI-999 include: Potency against FUZEON-sensitive viruses and slow,extended clearance about 6x greater than FUZEON which may allow them to be administered once weekly. The stock needs to close above the $13 level. bigcharts.marketwatch.com If it can do that it may get to test the $20 level.<g> bigcharts.marketwatch.com TRMS doesn't have a significant LTD, the insiders hold around 25% and the short ratio is around 20.<g> Bernard